FDA requests additional trial of Cinryze in acute indication
This article was originally published in Scrip
Executive Summary
ViroPharma has received a US FDA complete response letter for its supplemental BLA for Cinryze (C1 inhibitor (human)) for the treatment of acute attacks of hereditary angioedema (HAE).